Abstract
Dabigatran was shown effective for stroke prevention in atrial fibrillation (AF) in the RE-LY trial. Many pharmaceuticals are dosed according to body weight. We have previously shown the effect of Body Mass Index (BMI) on outcomes using BMI as a continuous variable. We augment that analysis by
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
